Literature DB >> 25640310

Understanding and treating aortopathy in bicuspid aortic valve.

Craig S Broberg1, Judith Therrien2.   

Abstract

Bicuspid aortic valve is a simple yet common condition with surprising clinical complexity. Patients are typically found to have enlargement of the ascending aorta, either root or midascending, independent of valve function. This enlargement is perceived to be a risk of aortic dissection, and therefore, prophylactic surgery is often recommended when the aorta reaches 50-55 mm in diameter. Despite the prevalence and potential health impact, there is to date no published data on the role of medical therapy. The emerging trend, however, is to address this question through clinical research. Early trials are underway designed to address the question of potential medical therapy. This article reviews current knowledge of the condition, its potential etiology, and ongoing work to assess the role of medical therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25640310     DOI: 10.1016/j.tcm.2014.12.006

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  3 in total

1.  Role of Computed Tomography in Assessment of the Thoracic Aorta.

Authors:  Nandini M Meyersohn; Khristine Ghemigian; Michael D Shapiro; Shimoli V Shah; Brian B Ghoshhajra; Maros Ferencik
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-08

2.  Clinical and echocardiographic determinants in bicuspid aortic dilatation: Results from a longitudinal observational study.

Authors:  Frederique E C M Peeters; Noreen Van der Linden; Alissa L L Thomassen; Harry J G M Crijns; Steven J R Meex; Bas L J H Kietselaer
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

Review 3.  Managing Thoracic Aortic Aneurysm in Patients with Bicuspid Aortic Valve Based on Aortic Root-Involvement.

Authors:  Elizabeth Norton; Bo Yang
Journal:  Front Physiol       Date:  2017-06-13       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.